Nimble radiopharma biotech Actithera secures $75M Series A to enter the clinic
Actithera, a nimble radiopharma biotech startup, has raised $75.5 million in a Series A funding round to support its entry into clinical development234.
The company was primarily led by CEO Andreas Goutopoulos, who initially set out to raise $50 million, but the round closed $25 million higher than anticipated at $75.5 million2.
Actithera operated largely as a one-person company for over a year and a half before this significant investment2.
The funding enables Actithera to initiate its first clinical trials, marking a pivotal transition from preclinical development to a clinic-ready biotech234.
Sources:
2. https://endpoints.news/nimble-radiopharma-biotech-actithera-gets-75m-to-enter-the-clinic/